J&J Forecasts Quicker EU Conversion To Cypher In Wake Of FDA Sign-Off
This article was originally published in The Gray Sheet
Executive Summary
U.S. approval of Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent will exert pressure on key European markets to pay for the device despite its significant price premium over conventional coronary stents, the company asserts